Concurrent chemoradiotherapy followed by consolidation chemotherapy with bi-weekly docetaxel and carboplatin for stage III unresectable, non-small-cell lung cancer: Clinical application of a protocol used in a previous phase II study

International Journal of Radiation Oncology Biology Physics

Volumn 82, Issue 5, 2012, Pages 1791-1796

  Saitoh, Jun Ichi ^a   Saito, Yoshihiro ^a   Kazumoto, Tomoko ^a   Kudo, Shigehiro ^a   Yoshida, Daisaku ^a   Ichikawa, Akihiro ^a   Sakai, Hiroshi ^a   Kurimoto, Futoshi ^a   Kato, Shingo ^b   Shibuya, Kei ^c  

^a SAITAMA CANCER CENTER   (Japan)

^b NATIONAL INSTITUTE OF RADIOLOGICAL SCIENCES   (Japan)

^c GUNMA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Carboplatin; Chemoradiotherapy; Consolidation chemotherapy; Docetaxel; Non small cell lung cancer

Indexed keywords

AREA UNDER THE CURVES; CARBOPLATIN; CAUSE-SPECIFIC SURVIVAL; CLINICAL APPLICATION; CONCURRENT CHEMORADIOTHERAPY; DOCETAXEL; ESOPHAGITIS; HEMATOLOGIC TOXICITY; LOCAL CONTROL; MEDIAN SURVIVAL; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL RATES; PHASE II; RADIATION PNEUMONITIS; TOTAL DOSE;

CHEMORADIOTHERAPY; CHEMOTHERAPY; RADIOTHERAPY;

DRUG PRODUCTS;

CARBOPLATIN; DOCETAXEL;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD TOXICITY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CAUSE SPECIFIC SURVIVAL; CHEMORADIOTHERAPY; CLINICAL PROTOCOL; CONSOLIDATION CHEMOTHERAPY; DISEASE CONTROL; DISEASE SEVERITY; ESOPHAGITIS; FEASIBILITY STUDY; FEMALE; HISTOLOGY; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RADIATION DOSE; RADIATION FIELD; RADIATION PNEUMONIA; SURVIVAL TIME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AREA UNDER CURVE; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; CHEMORADIOTHERAPY; CLINICAL TRIALS, PHASE II AS TOPIC; CONSOLIDATION CHEMOTHERAPY; DOSE FRACTIONATION; DRUG ADMINISTRATION SCHEDULE; ESOPHAGITIS; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; RADIATION PNEUMONITIS; SURVIVAL RATE; TAXOIDS;

EID: 84858701956     PISSN: 03603016     EISSN: 1879355X     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2011.03.007     Document Type: Article

References (22)

1. Pritchard RS, Anthony SP. Chemotherapy plus radiotherapy compared with radiotherapy alone in the treatment of locally advanced, unresectable, non-small-cell lung cancer. A meta-analysis. Ann Intern Med 1996;125(9):723-729. (Pubitemid 126450359)
2. Marino P, Preatoni A, Cantoni A. Randomized trials of radio-therapy alone versus combined chemotherapy and radiotherapy in stages IIIa and IIIb nonsmall cell lung cancer. A meta-analysis. Cancer 1995;76(4):593-601.
3. Pfister DG, Johnson DH, Azzoli CG, et al. American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: Update 2003. J Clin Oncol 2004; 22(2):330-353. (Pubitemid 41095099)
4. Green MR, Rocha Lima CM, Sherman CA. Radiation and chemotherapy for patients with stage III non-small-cell lung cancer. Semin Radiat Oncol 2000;10(4):289-295.
5. Furuse K, Fukuoka M, Kawahara M, et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol 1999; 17(9):2692-2699. (Pubitemid 29415225)
6. Zatloukal P, Petruzelka L, Zemanova M, et al. Concurrent versus sequential chemoradiotherapy with cisplatin and vinorelbine in locally advanced non-small cell lung cancer: A randomized study. Lung Cancer 2004;46(1):87-98. (Pubitemid 39201387)
7. Choy H, Rodriguez F, Koester S, et al. Synergistic effects of Taxol/Taxotere on radiation sensitivity of human cell lines. Int J Radiat Oncol Biol Phys 1993;24(Suppl 1):1059.
8. Mason KA, Hunter NR, Milas M, et al. Docetaxel enhances tumor radioresponse in vivo. Clin Cancer Res 1997;3:2431-2438. (Pubitemid 28133165)
9. Mason KA, Kishi K, Hunter N, et al. Effect of docetaxel on the therapeutic ratio of fractionated radiotherapy in vivo. Clin Cancer Res 1999;5(12):4191-4198. (Pubitemid 30013805)
10. Douple EB, Richmond RC, O'Hara JA, et al. Carboplatin as a potentiator of radiation therapy. Cancer Treat Rep 1985;12: 111-124. (Pubitemid 16167908)
11. Sakai H, Yoneda S, Kobayashi K, et al. Phase II study of bi-weekly docetaxel and carboplatin with concurrent thoracic radiation therapy followed by consolidation chemotherapy with docetaxel plus carboplatin for stage III unresectable nonsmall cell lung cancer. Lung Cancer 2004;43(2):195-201. (Pubitemid 38114748)
12. Kiura K, Ueoka H, Segawa Y, et al. Phase I/II study of doce-taxel and cisplatin with concurrent thoracic radiation therapy for locally advanced non-small-cell lung cancer. Br J Cancer 2003;89(5):795-802. (Pubitemid 37175797)
13. Segawa Y, Kiura K, Takigawa N, et al. Phase III trial comparing docetaxel and cisplatin combination chemotherapy with mitomycin, vindesine, and cisplatin combination chemotherapy with concurrent thoracic radiotherapy in locally advanced non-small-cell lung cancer: OLCSG 0007. J Clin Oncol 2010; 28(20):3299-3306.
14. Nakamura M, Koizumi T, Hayasaka M, et al. Cisplatin and weekly docetaxel with concurrent thoracic radiotherapy for locally advanced stage III non-small-cell lung cancer. Cancer Chemother Pharmacol 2009;63(6):1091-1096.
15. Iwasaki Y, Ohsugi S, Natsuhara A, et al. Phase I/II trial of biweekly docetaxel and cisplatin with concurrent thoracic radiation for stage III non-small-cell lung cancer. Cancer Chemother Pharmacol 2006;58(6):735-741. (Pubitemid 44351252)
16. Jain AK, Hughes RS, Sandler AB, et al. A phase II study of concurrent chemoradiation with weekly docetaxel, carboplatin, and radiation therapy followed by consolidation chemotherapy with docetaxel and carboplatin for locally advanced inoperable non-small cell lung cancer (NSCLC). J Thorac Oncol 2009; 4(6):722-727.
17. Bradley J, Graham MV, Winter K, et al. Toxicity and outcome results of RTOG 9311: A phase I-II dose-escalation study using three-dimensional conformal radiotherapy in patients with inoperable non-small-cell lung carcinoma. Int J Radiat Oncol Biol Phys 2005;61(2):318-328. (Pubitemid 40164423)
18. Bradley J. A review of radiation dose escalation trials for non-small cell lung cancer within the Radiation Therapy Oncology Group. Semin Oncol 2005;32(2, Suppl. 3):S111-S113.
19. Katayama H, Ueoka H, Kiura K, et al. Preoperative concurrent chemoradiotherapy with cisplatin and docetaxel in patients with locally advanced non-small-cell lung cancer. Br J Cancer 2004;90(5):979-984. (Pubitemid 38495815)
20. Friedel G, Budach W, Dippon J, et al. Phase II trial of a trimodality regimen for stage III non-small-cell lung cancer using chemotherapy as induction treatment with concurrent hyperfractionated chemoradiation with carboplatin and paclitaxel followed by subsequent resection: A single-center study. J Clin Oncol 2010;28(6):942-948.
21. Hehr T, Friedel G, Steger V, et al. Neoadjuvant chemoradiation with paclitaxel/carboplatin for selected Stage III non-small- cell lung cancer: Long-term results of a trimodality Phase II protocol. Int J Radiat Oncol Biol Phys 2010;76(5): 1376-1381.
22. Kaya AO, Buyukberber S, Benekli M, et al. Concomitant chemoradiotherapy with cisplatin and docetaxel followed by surgery and consolidation chemotherapy in patients with unresectable locally advanced non-small cell lung cancer. Med Oncol 2010;27(1):152-157.